Content about chemotherapy

February 24, 2012
Study: Walgreens Specialty Pharmacy can cut infusion medication costs by more than half

Walgreens Specialty Pharmacy on Thursday released data showing that both patients and their health plans can realize savings of up to 60% on the cost of infused specialty medications by choosing alternate treatment sites.

February 23, 2012
Galen acquires DaunoXome from Gilead

A Northern Ireland pharmaceutical company has acquired a chemotherapy agent from Gilead.

February 22, 2012
Psi Bands recipient of Kimberly-Clark's Huggies MomInspired Grant

Psi Bands on Wednesday announced its line of fashionable nausea-relief bands was recently recognized with Kimberly Clark's Huggies MomInspired Grant, a grant program designed to recognize and support inspirational and entrepreneurial moms.

January 19, 2012
Sandoz starts two late-stage biosimilar trials

Drug maker Sandoz has started two late-stage clinical trials of biosimilar drugs for treating cancer patients undergoing chemotherapy, the company said Thursday, saying the studies were meant to support the drugs' eventual marketing in the United States.

November 18, 2011
FDA approves Erwinaze for acute lymphoblastic leukemia

The Food and Drug Administration has approved a new chemotherapy drug for treating acute lymphoblastic leukemia, the agency said Friday.

November 8, 2011
U of Arizona Cancer Center partners with Walgreens on specialty pharmacy

The University of Arizona Cancer Center, in partnership with Walgreens, last month opened a specialty outpatient pharmacy on-site to meet the needs of its patients.

November 7, 2011
FDA gives new approval to Bristol-Myers Squibb's, Lilly's Erbitux

The Food and Drug Administration has approved a drug made by Bristol-Myers Squibb for treating head and neck cancer, the agency said Monday.

September 28, 2011
Sagent's chemotherapy drug enters market

Sagent Pharmaceuticals has launched its new chemotherapy drug.

September 27, 2011
Study: Lilly drug keeps common lung cancer under control in elderly patients

A drug made by Eli Lilly prevented the most common form of lung cancer from progressing in elderly patients when added to chemotherapy, according to results of a late-stage clinical trial.

September 22, 2011
J&J HIV drug shows fewer side effects in trial data analysis

A new study has found that a recently approved drug for HIV produces fewer unpleasant side effects during the first three months of therapy than the standard treatment, according to published reports.

September 21, 2011
Mylan, Roche reach deal over cancer drug

Generic drug maker Mylan has entered an agreement with Hoffmann La Roche concerning its version of an oral chemotherapy drug.

August 23, 2011
Sandoz announces FDA approval, U.S. launch of chemotherapy drug

The Food and Drug Administration has approved a chemotherapy drug made by Sandoz, the drug maker said Tuesday.

August 18, 2011
Researcher: Cancer patients ought to confer with doctors on supplement use

Acai berry, cumin, herbal tea, turmeric and long-term use of garlic may negatively impact chemotherapy treatment, according to a new report released Wednesday that originally was presented at the American Society of Clinical Oncology meeting in Chicago this summer.

August 9, 2011
FDA approves Hospira cancer drug

The Food and Drug Administration has approved a generic chemotherapy drug made by Hospira, the drug maker said.

August 2, 2011
Merrimack gets orphan drug designation for pancreatic cancer treatment

The Food and Drug Administration has granted orphan drug designation to a chemotherapy drug made by Merrimack Pharmaceuticals for pancreatic cancer, the drug maker said Monday.

April 27, 2011
Investigational drug, in combo with chemo, shown to help colorectal cancer patients survive longer

An investigational drug helped patients survive longer when combined with chemotherapy as a second-line treatment for colorectal cancer that had spread to other parts of the body, according to results of a late-stage clinical trial announced by French drug maker Sanofi-Aventis and U.S.-based Regeneron Pharmaceuticals.

April 25, 2011
AP Pharma announces financing, appoints new executives

Drug maker AP Pharma has appointed two new executives and may receive financing of up to $4.5 million, the company said Monday.

March 24, 2011
Bristol: Ipilimumab boosts survival rates among patients in phase-3 trial

Bristol-Myers Squibb said its late-stage clinical trial for a cancer treatment, which currently is under review by the Food and Drug Administration, achieved its primary endpoint.

February 9, 2011
Genentech: Avastin boosts chances of progression-free survival among ovarian cancer patients

Women with ovarian cancer who received a drug made by Genentech lived longer without their disease becoming worse, according to a late-stage clinical trial.

January 26, 2011
Teva, APP develop generic Gemzar

Generic drug makers Teva Pharmaceutical Industries and APP Pharmaceuticals have launched their version of a chemotherapy drug, the two companies said Wednesday.

January 19, 2011
Genentech appeals FDA's plan to pull Avastin off market

Drug maker Genentech is hoping to keep a breast cancer treatment on the market as the Food and Drug Administration considers whether to revoke its approval for the disease, according to published reports.

January 6, 2011
AdventRx's application for Exelbine accepted by FDA

The Food and Drug Administration has accepted the approval application for a chemotherapy drug to treat lung cancer from AdventRx Pharmaceuticals, the drug maker said Thursday.

January 5, 2011
Senator to float bill to address drug shortages

Responding to what she termed an “unprecedented” shortage of prescription medicines for such serious conditions as cancer, Sen. Amy Klobuchar, D-Minn., is promising new legislation to deal with the problem.

January 3, 2011
3Rx Skin Therapy's new line targets skin damaged by medical conditions

3Rx Skin Therapy has announced the introduction of a new skin care line to help repair and rejuvenate skin damaged by such cancer treatments as chemotherapy and radiation, and other dry skin issues caused by medical conditions.

December 8, 2010
Decision Resources: J&J, Merck chemotherapy drugs will emerge as go-to second-line treatments

Chemotherapy drugs made by Johnson & Johnson and Merck will become the standard second-line treatment for ovarian cancer within the decade, replacing a treatment made by Bristol-Myers Squibb and generic versions, according to a new report by market research firm Decision Resources.

© 2013 Drug Store News. All Rights Reserved.